PURE Bioscience (OTCMKTS:PURE) Releases Quarterly Earnings Results

PURE Bioscience (OTCMKTS:PURE) announced its quarterly earnings data on Monday. The company reported ($0.01) earnings per share (EPS) for the quarter, Zacks reports. The company had revenue of $0.49 million during the quarter.

PURE Bioscience Price Performance

PURE Bioscience stock opened at $0.09 on Wednesday. The company has a market capitalization of $9.53 million, a price-to-earnings ratio of -2.13 and a beta of 0.35. PURE Bioscience has a one year low of $0.05 and a one year high of $0.21. The company’s fifty day moving average price is $0.08 and its two-hundred day moving average price is $0.07.

About PURE Bioscience

PURE Bioscience, Inc develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company manufactures and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds.